REGENERON PHARMACEUTICALS INC

Member Only Articles

AI Health Factor Performance Trends

Latest Insights

04 February, 2025
Regeneron Pharmaceuticals Positioned for Growth Amidst Mixed Market Sentiments and Upcoming Earnings Reports
Read More >>
03 February, 2025
Regeneron Pharmaceuticals Positioned for Growth Amidst Mixed Market Sentiments and Upcoming Earnings Reports
Regeneron Pharmaceuticals (REGN) continues to be a strong player in the biotech sector, recognized as one of the top holdings in the SPDR S&P 500 ETF Trust (SPY). Currently, SPY has seen a notable inc...
Read More
02 February, 2025
Regeneron Faces Scrutiny Amid 2024 Declines as Upcoming Earnings Reports Loom
Regeneron Pharmaceuticals (REGN) is navigating a challenging landscape after facing a notable 28.8% stock decline in 2024. As the company prepares to release its fourth-quarter and full-year 2024 resu...
Read More
01 February, 2025
Regeneron Faces Scrutiny Amid 2024 Declines as Upcoming Earnings Reports Loom
Regeneron Pharmaceuticals (REGN) is navigating a challenging landscape after facing a notable 28.8% stock decline in 2024. As the company prepares to release its fourth-quarter and full-year 2024 resu...
Read More
31 January, 2025
Regeneron Reports Mixed Sales for Eylea Amidst Competitive Market Pressure from Roche's Vabysmo
Regeneron Pharmaceuticals has recently reported sales figures that reveal both successes and challenges for the company, particularly with its eye medication, Eylea. In the last quarter, Regeneron gen...
Read More

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.